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Abstract
Cytoskeleton disorganization is an early step in the ac-
tivation process of matrix metalloproteinase 2 (MMP-2)
by membrane type 1 MMP (MT1-MMP) but is also as-
sociated with endoplasmic reticulum (ER) dysfunction
and subsequent cell death. Given evidence that the
ER-embedded glucose-6-phosphate transporter (G6PT)
regulates glioblastoma cell survival and that MT1-
MMP is a key enzyme in the cancer cell invasive pheno-
type, we explored the molecular link between G6PT
and MT1-MMP. Cytoskeleton-disrupting agents such as
concanavalin A (ConA) and cytochalasin D triggered
proMMP-2 activation and cell death in U87 glioma cells.
ConA decreased G6PT gene expression, an event that
was also observed in cells overexpressing the full-
length recombinant MT1-MMP protein. Overexpression
of a membrane-bound catalytically active but cytoplas-
mic domain–deleted MT1-MMP was unable to down-
regulate G6PT gene expression or to trigger necrosis.
Gene silencing of MT1-MMP with small interfering RNA
prevented proMMP-2 activation and induced G6PT
gene expression. ConA inhibited Akt phosphorylation,
whereas overexpression of recombinant G6PT rescued
the cells from ConA-induced proMMP-2 activation and
increased Akt phosphorylation. Altogether, new func-
tions of MT1-MMP in cell death signaling may be linked
to those of G6PT. Our study indicates a molecular sig-
naling axis regulating the invasive phenotype of brain
tumor cells and highlights a new ‘‘bioswitch’’ function
for G6PT in cell survival.
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Introduction
The endoplasmic reticulum (ER) is a membrane-bound
organelle present in all eukaryotic cells. Recently, ER stress
signaling has been linked to disease states involving insulin
resistance, disordered lipid metabolism, and hypoxia toler-
ance in tumor progression [1,2]. In addition, the ER is a
multifunctional metabolic compartment that controls entry and
release of calcium, sterol biosynthesis, apoptosis, and the
release of arachidonic acid [3,4]. Despite its complex organi-
zation, the ER is a continuous membrane compartment whose
architecture depends on microtubule dynamics [5]. The ER is
primarily known as the site of synthesis and folding of secreted,
membrane-bound, and some organelle-targeted proteins. Re-
cent evidence suggests that the microtubulin cytoskeleton and
the centrosomes (the microtubulin cytoskeleton–organizing
centers) are essential for the trafficking and internalization
of ‘the membrane-bound matrix metalloproteinase MT1-
MMP [6], involved in brain tumor cell invasion, extracellular
matrix (ECM) degradation and cell–ECM interaction [7]. Inter-
estingly, altered expression, maturation and trafficking of MT1-
MMP to the plasma membrane were observed in diabetic
states [8,9], a condition known to upregulate the expression
of an ER-embedded protein, the glucose-6-phosphate trans-
porter (G6PT) [10]. G6PT expression was shown to be down-
regulated by MT1-MMP in bone marrow–derived stromal
cells, where it was suggested to provide a molecular link
between proMMP-2 activation and chemotaxis processes in
cell mobilization [11].
Several factors are required for optimum protein folding,
including ATP, Ca2+, and an oxidizing environment that will allow
disulfide-bond formation [12]. Because of this specialized envi-
ronment requirement, the stresses that perturb cellular energy
levels, redox state, or Ca2+ concentration can often result in the
intracellular accumulation of unfolded protein, which is called
ER stress response. Recently, we have provided evidence that
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G6PT regulated U87 glioma cell chemotaxis [13] and sur-
vival [14]. Tumor cells often show evidence of constitutive
ER stress, possibly due to hypoxia and glucose depletion [15].
In fact, the ATP-depleting agents and ER stress inducers
2-deoxyglucose and 5-thioglucose have been shown to in-
hibit MMP-2 secretion from U87 glioma cells [13], a process
known to contribute to tumor development [16]. G6PT is
thought to have a role in sequestering intracellular Ca2+ within
the ER through an ATP-mediated process [17]. Because
manipulating the ER stress response of tumor cells is a prom-
ising therapeutic strategy [15] and because various anti-
cancer drugs have been shown to induce ER stress and to
affect the invasive or metabolic control of cancer cells [18,19],
we explored the potential molecular link between MT1-MMP
and G6PT functions within the ER that could potentially
regulate the brain tumor cell invasive phenotype.
Results
Differential Induction of Cell Necrosis and Cell Apoptosis
by Cytoskeleton-Disrupting Agents
Concanavalin A (ConA) and cytochalasin D (CytoD) have
been shown to disrupt the cytoskeleton architecture [20].
After cell staining with annexin V/propidium iodide (PI),
flow cytometry was used to assess the extent of cell death
induced by both agents. From the side scatter (SSC)/forward
scatter (FSC) plots, the changes in cell ‘‘morphology’’ fea-
tures that each agent induced are clearly visible (Figure 1A).
When annexin V/PI cell staining was performed, ConA treat-
ment resulted in a marked increase in necrosis (Figure 1A,
bottom, upper left quadrant), whereas CytoD triggered late
apoptosis (Figure 1A, bottom, upper right quadrant). Cell
viability and total cell death were quantified (Figure 1B).
Furthermore, cell necrosis and cell apoptosis (early and late)
(Figure 1C) were also separately quantified to show the
differential induction of necrosis by ConA and induction of
apoptosis by CytoD.
Recombinant MT1-MMP and Cytoskeleton-Disrupting
Agents Induce proMMP-2 Activation
Latent proMMP-2 activation into its active MMP-2 form
has been correlated with cell death [21,22]. Accordingly,
we have previously shown that the cytoskeleton-disrupting
agents ConA and CytoD triggered proMMP-2 activation in
U87 glioma cells [23]. Using fluorescent microscopy, we vali-
dated overexpression of full-length wild-type (wt) recombinant
MT1-MMP or the membrane-bound cytoplasmic-deleted
Figure 1. Differential induction of cell necrosis and cell apoptosis by cytoskeleton-disrupting agents. U87 glioblastoma cells were cultured as described in the
Materials and Methods section until they reachedf75% to 90% confluence. They were then serum-starved for 24 hours before the addition of 10 g/ml ConA or
1 mol/l CytoD (CD). Incubation was continued for another 24 hours. (A) Flow cytometry was then used to either assess light-scattering properties associated with
changes in cell morphology (top panels) or cell death from annexin V/PI-stained cells (bottom panels). (B) Cell viability (white columns) was assessed as the
percentage of total cells present in the lower left quadrants. Cell death (black columns) represents the combined cells present in necrosis, early/late apoptosis
(black columns). (C) The respective cell death proportions attributable to either necrosis or apoptosis (early and late) are shown. Data are the averages ± SEM of
four independent experiments. Statistical significance is represented by (*).
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recombinant MT1-MMP both fused to green fluorescent pro-
tein (GFP) (Figure 2A) and consequent proMMP-2 activation
demonstrated by gelatin zymography (Figure 2B). Transfec-
tions of cells with cDNA encoding GFP alone did not affect
the ability of ConA or CytoD to induce proMMP-2 activation
(data not shown). These results suggest that, similar to
cytoskeleton-disrupting agents ConA and CytoD, MT1-
MMP–mediated proMMP-2 activation is also potentially
linked to the control of cell survival in U87 glioma cells.
ConA-Mediated Activation of proMMP-2
Requires MT1-MMP
To assess the involvement of MT1-MMP in the proMMP-2
activation process and the necrotic effects of ConA, we spe-
cifically downregulated MT1-MMP gene expression using a
specific MT1-MMP gene silencing strategy [24]. Cells were
transfected with mismatched (Mock) or MT1-MMP–targeted
small interfering RNA (siRNA) duplexes, as described in the
Materials and Methods section, and then treated with in-
creasing concentrations of ConA. Total RNA was isolated
and reverse transcription–polymerase chain reaction (RT-
PCR) confirmed that MT1-MMP gene downregulation was
successfully achieved (Figure 3A). Conditioned media from
these conditions were also isolated to assess the MT1-MMP–
mediated proMMP-2 activation by ConA. Gelatin zymography
clearly showed significantly decreased proMMP-2 activation
in the cells in which MT1-MMP gene expression had been
knocked down (Figure 3B). This was quantified by scanning
densitometry, showing close to 90% inhibition (data not
shown). This clearly suggests that the ConA-mediated events
that we previously observed involve MT1-MMP in proMMP-2
activation and are likely involved in cell death.
MT1-MMP Cytoplasmic Domain Is Responsible for Cell
Death Signaling
Although extracellular catalytic inhibition of MT1-MMP
only partially reversed its ability to trigger cell death [11],
the implication of MT1-MMP in signaling intracellular cell
death processes was thus evaluated. Transient transfection
using cDNA plasmids encoding either the full-length or the
membrane-bound cytoplasmic-deleted recombinant forms of
MT1-MMP was performed in U87 glioma cells. Annexin V/PI
staining was then performed and cell death (necrosis and
apoptosis) was assessed by flow cytometry (Figure 4A).
Overexpression of native MT1-MMP significantly triggered
cell necrosis by more than 10 times, whereas cell apoptosis
was also induced approximately twofold (Figure 4B, gray
bars). Although still catalytically active at the cell surface
(Figure 2B), the deletion of the MT1-MMP cytoplasmic
domain significantly abrogated the induction of both cell
Figure 2. Recombinant MT1-MMP and cytoskeleton-disrupting agents induce proMMP-2 activation. U87 glioblastoma cells were treated as described in the legend
to Figure 1. Transfections of cDNA plasmids encoding full-length Wt-MT1-MMP and cytoplasmic domain– truncated MT1-MMP both fused to GFP were carried out
as described in the Materials and Methods section. (A) Changes in cell morphology are shown through phase-contrast microphotography (visible light), whereas
transfection efficiency was validated by fluorescence microscopy. (B) Gelatin zymography was carried out to assess the extent of proMMP-2 activation levels, as
described in the Materials and Methods section, using conditioned media isolated from each of the serum-starved cell conditions.
Figure 3. ConA-mediated activation is an MT1-MMP–mediated event.
Because proMMP-2 activation is thought to proceed through an MT1-MMP–
mediated event, U87 glioblastoma cells were transfected with siRNA against
MT1-MMP or mismatched siRNA (Mock) for 48 hours, as described in the
Materials and Methods section, before treatment with increasing concen-
trations of ConA. (A) Total RNA was isolated and MT1-MMP gene expression
was assessed by RT-PCR as described in the Materials and Methods
section. The gene expression level of GAPDH was used as the internal
control. (B) Gelatin zymography was performed to assess the extent of
proMMP-2 activation in the conditioned media of serum-starved Mock and
siMT1-MMP cells treated with increasing concentrations of ConA.
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necrosis and apoptosis (Figure 4B, black bars). These
observations suggest that active MMP-2 is not responsible
for cell death and that some MT1-MMP–mediated intracel-
lular signaling is a prerequisite for the control of cell survival.
MT1-MMP Overexpression and ConA Treatment
Downregulate G6PT Gene Expression
To investigate the intracellular events involved in MT1-
MMP– and ConA-mediated cell death, we examined the
prosurvival microsomal glucose-6-phosphate translocase
(G6PT) as a potential link. Cytoskeleton disruption is often
linked to ER stress [25,26], and silencing of G6PT, a micro-
somal resident protein, has recently been shown to in-
duce cell death in U87 glioma cells [14]. We thus isolated
total RNA from ConA-treated cells and from MT1-MMP–
transfected cells because cell necrosis was a common
event in both conditions. RT-PCR was performed as de-
scribed in the Materials and Methods section and we found
that G6PT gene expression was significantly reduced in
ConA-treated and in the MT1-MMP–transfected cells (Fig-
ure 5A). Interestingly, in agreement with its inability to trigger
cell death, deletion of MT1-MMP’s cytoplasmic domain
was also ineffective in reducing G6PT gene expression.
Gene expression of glucose-6-phosphatase (G6Pase)-b,
the only other component of the G6Pase system that was
expressed in U87 cells [13] and of GAPDH remained unaf-
fected and can be considered as unaffected internal controls
(Figure 5A). ConA treatment and MT1-MMP overexpression
resulted, as expected, in an increase in MT1-MMP transcript
levels. Altogether, this demonstrates that necrosis-inducing
Figure 4. MT1-MMP overexpression triggers cell death and is signaled through its intracellular cytoplasmic domain. U87 glioblastoma cells were transfected
with cDNA encoding full-length Wt-MT1-MMP or its cytoplasmic domain– truncated form as described in the Materials and Methods section. (A) Flow cytometry
was used to assess the extent of cell death in annexin V/PI-stained cells. (B) Quantification of cell death caused by either combined early and late apoptosis (upper
and lower right quadrants) or necrosis (upper left quadrants) was performed for cells transfected with cytoplasmic domain– truncated MT1-MMP (D-cyto) or
full-length Wt-MT1-MMP.
Figure 5. Both MT1-MMP overexpression and ConA treatment downregu-
late G6PT gene and protein expression. (A) Total RNA was isolated from
untreated (Mock), ConA-treated, or U87 glioblastoma cells transfected with
either the cytoplasmic domain– truncated MT1-MMP (D-cyto) or full-length Wt-
MT1-MMP cDNA. RT-PCR was performed to assess the changes in G6PT,
G6Pase-, GAPDH, or MT1-MMP gene expression in each condition. (B) MT1-
MMP gene expression was specifically downregulated in U87 glioblastoma
cells transfected with siMT1-MMP but not in mismatched siRNA-transfected
cells (Mock) as described in the Materials and Methods section. Total RNA and
RT-PCR were performed as in (A). (C) Cell lysates were isolated from U87
cells transfected with cDNA encoding G6PT, Wt-MT1-MMP, or D-cyto MT1-
MMP, or treated with ConA. Western blotting and immunodetection was per-
formed with anti-G6PT and anti-GAPDH antibodies.
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conditions, such as those triggered by ConA or overexpres-
sion of recombinant MT1-MMP, are molecularly linked to
the prosurvival functions of G6PT. Interestingly, when MT1-
MMP gene expression was silenced, the expression of G6PT
increased significantly in comparison to the mismatched
siRNA-transfected cells (Mock), suggesting that MT1-MMP
exerted a repressive effect on G6PT gene regulation (Fig-
ure 5B). Modulation of G6PT gene expression was further
confirmed at the protein level. We showed that ConA treat-
ment or Wt-MT1-MMP overexpression downregulated G6PT
protein expression (Figure 5C). Thus, our results show that
G6PT gene regulation is signaled by the intracellular MT1-
MMP cytoplasmic domain.
G6PT Overexpression Antagonizes the ConA-Mediated
Lethal Effect
To characterize the molecular mechanism linking MT1-
MMP to G6PT, we next assessed whether constitutively ex-
pressed recombinant G6PTcould overcome the lethal effect
of ConA. MT1-MMP synthesis by a mechanism that involves
phosphatidylinositol-3 kinase (PI3K)/Akt/mTOR was recently
highlighted [27] and, thus, Akt phosphorylation state was
explored. U87 cells were transiently transfected with cDNA
encoding G6PT and then treated with the cell death inducer
ConA. Immunodetection of total and phosphorylated Akt
was performed on Mock and G6PT-transfected cell lysates.
We observed that ConA decreased the basal levels of
phosphorylated Akt by up to 50%, although not of total Akt
protein expression, in Mock-transfected cells (Figure 6A).
Transient overexpression of recombinant G6PT completely
reversed the effects of ConA on Akt phosphorylation (Fig-
ure 6B). Despite being more associative than mechanistic,
these observations confirm the G6PT prosurvival activity
[14] and show that targeting PI3K/Akt signaling by ConA
induces apoptosis [28]. Finally, we showed by zymography
that G6PT overexpression significantly antagonized ConA-
mediated proMMP-2 activation (Figure 6C), an effect that
may involve inhibiting MT1-MMP functions.
Discussion
Gliomas remain a great challenge in oncology today as they
account for more than 50% of all brain tumors and are by far
the most common primary brain tumors in adults [29]. More
importantly, the mechanisms involved in the resistance of
migrating glioblastoma cells to chemotherapy or to radiation-
induced cell death have long been recognized [30] and still
receive much attention in order to optimize future cellular
targets for the treatment of glioblastomas [31]. A relationship
between cell migration and apoptosis was highlighted by the
observations that resistance to apoptosis is closely linked to
tumorigenesis, but that paradoxically migrating tumor cells
can also still be induced to die by nonapoptotic mechanisms
such as necrosis [32]. In fact, tissue necrosis is a character-
istic feature of malignant gliomas, in particular glioblastoma,
and is most likely the consequence of rapidly increasing tumor
mass that is inadequately oxygenated by the preexisting
vasculature [33]. Because tumor cells respond to hypoxic
stress by upregulating a variety of genes involved in glucose
uptake, glycolysis, and angiogenesis, all essential to main-
taining nutrient availability and intracellular ATP levels [34],
the intracellular metabolic compartments regulating cell sur-
vival and invasiveness are of particular interest. Besides
mitochondria and lysosomes, the ER is very important in this
respect, as it is now recognized as an important sensor of
cellular stress and plays a key role in the release and acti-
vation of death factors such as cathepsins, calpains, and other
proteases through intracellular calcium flux [35]. For instance,
migrating glioblastoma cells have recently been shown to
overexpress death-associated protein-3 [36]. Therefore, new
routes should be investigated as possible issues to combat
apoptotic-resistant migrating glioblastoma cells.
Given the ER localization of G6PTand the crucial role that
the ER plays as a metabolic compartment, we suggest that
G6PT is a key mediator in the regulation of cancer cell sur-
vival and ECM degradation signaling. In fact, regulation of
G6PT expression may function as a ‘‘bioswitch’’ (Figure 7A)
enabling cells to promote either migration or cell death pro-
cesses. Switching from one state to another may occur in
response to external stimuli, such as hypoxia, or as a result
of intracellular metabolic changes [37]. Intracellular regula-
tion of Ca2+ flux and cytosolic ATP and G6P levels are
among the parameters that G6PTmay modulate in the trans-
formed proliferating cells. As such, metabolic profiling of cell
growth and death in cancer is already used to identify the
changes in glucose utilization for macromolecule synthesis
in cancer [38,39]. Among the several brain tumor–derived
cell lines tested, G6PT expression was found the highest in
the highly infiltrating and angiogenic U87 glioma cells [13].
This potentially suggests that metabolic adaptive capacity, in
part through G6PT, may regulate the invasive phenotype of
aggressive cancer cells. Documenting the pleiotropic roles
Figure 6. G6PT overexpression antagonizes the ConA-mediated lethal effect.
(A) Mock or G6PT-transfected U87 cells were treated with increasing ConA
concentrations and cell lysates were used to immunodetect the levels of total
or phosphorylated Akt (p-Akt). (B) Scanning densitometry was used to quantify
the Akt immunoreactive bands, and results were expressed as the ratio of
p-Akt over Akt. (C) Conditioned media isolated from serum-starved Mock,
siMT1-MMP (siMT1), or G6PT-transfected U87 cells were used to perform
gelatin zymography.
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of G6PT in cancer cells will thus help optimize or design new
antitumor therapies.
We previously showed that inhibiting G6PT function by
chlorogenic acid or by ATP-depleting agents such as 2-
deoxyglucose in brain tumor–derived cells did not directly
affect MT1-MMP catalytic function but still resulted in de-
creased invasiveness [13]. Moreover, cancer cells frequently
display high rates of aerobic glycolysis compared with their
nontransformed counterparts, and the possible applications
of 2-deoxyglucose in anticancer therapies further support the
theory that inhibiting G6PT function in cancer cells could
decrease tumor progression. Some evidence also suggests
that ER stress-inducing agents are useful as cancer agents
and that excessive ER stress leads to apoptosis. These
agents include glycosylation inhibitors (e.g., tunicamycin
and 2-deoxyglucose), agents that deplete ER Ca2+ (e.g.,
the sarcoendoplasmic reticulum Ca2+-ATPase inhibitor thap-
sigargin and various ionophores) and agents that induce
reductive stress (dithiotreitol and b-mercaptoethanol) [40].
We also found that cytoskeleton remodeling is among the
first events in a cascade of activation that leads to MT1-
MMP–mediated downregulation of brain cancer cell survival,
in part through PI3K/Akt-mediated plasma membrane to
nucleus signaling. Interestingly, part of the switch between
cell migration and cell death comes under the control of the
PTEN/Akt/PI3K/mTOR pathway [30]. Survival through PI3K/
Akt signaling is complex [41] and the activity of the PI3K/Akt
pathway is, in fact, often upregulated in brain tumors as a
result of excessive stimulation by growth factor receptors
and Ras [42]. Moreover, glioblastomas frequently carry
mutations in the PTEN tumor suppressor gene, whose tumor
suppressor properties are closely related to its inhibitory
effect on the PI3K-dependent activation of Akt signaling
[43]. The activation of the PI3K pathway is significantly
associated with increasing tumor grade, lower levels of
apoptosis, and an adverse clinical outcome in the case of
human gliomas [44]. All these factors indicate that aberrant
PI3K/Akt signaling means that both cell proliferation in
glioma cells and cell migration have become abnormal. A
number of publications have already reported that an aber-
rantly activated PI3K/Akt pathway renders tumor cells resis-
tant to cytotoxic insults, including those related to anticancer
drugs [45,46]. In light of these results and because G6PT
was able to reverse the cytotoxic effects of ConA, it is
tempting to suggest that functional targeting of G6PT such
as by the use of chlorogenic acid or by its analogs, the most
potent G6PT inhibitors, could augment the effectiveness of
chemotherapy on glioma cells.
Maintenance of cytoarchitecture is required for cell sur-
vival because its perturbation by CytoD- or ConA-mediated
MT1-MMP mechanisms diminished cell survival and were
correlated to proMMP-2 activation [21,22] (this study). In fact,
silencing of the MT1-MMP gene prevented ConA from acti-
vating proMMP-2. Moreover, we showed that the intracellular
domain of MT1-MMP is an absolute requirement for trans-
ducing the intracellular signaling that leads to cell death.
Although the exact identity of the amino acid residues from
the MT1-MMP intracellular domain remains to be addressed,
speculations about the Tyr573, Cys574, and Val582 have
been put forward as important for MT1-MMP signaling
[47,48]. Similarly, a caspase-dependent mechanism has re-
cently been associated with MT1-MMP function in endothelial
cell morphogenic differentiation [49]. This suggests that
MT1-MMP acts as a potential cell death sensor/effector
that signals ECM degradation processes to be activated. In-
terestingly, hypoxia increased levels of MT1-MMP and the
MT1-MMP transcription factor regulator Egr-1 in bone
marrow–derived stromal cells [50], a condition that led to
cell death [51]. Moreover, ConA was found ineffective in ac-
tivating proMMP-2 or inhibiting G6PT gene expression in
bone marrow stromal cells isolated from Egr-1/mouse [11].
The fact that G6PT overexpression inhibited ConA-
induced proMMP-2 activation, but not cell death, further
suggests that complex differential regulation takes place
and highlights the pleiotropic intracellular functions of
G6PT. Moreover, this observation also provides insight into
the cellular event chronology, confirming that MT1-MMP–
mediated activity and signaling are among the first steps that
inhibit G6PT expression, ultimately leading to cell death.
Figure 7. G6PT as a bioswitch intermediate in the regulation of proMMP-2
activation and cell death signaling. (A) Summarized scheme of the events
that lead to MT1-MMP–mediated signaling in proMMP-2 activation and in cell
death. ConA upregulates MT1-MMP gene and protein expression, which
in turn downregulates G6PT expression (1). Low levels of G6PT release
the inhibitory effect on MT1-MMP–mediated proMMP-2 activation (2), which
altogether leads to ECM degradation and cell invasion. When a specific
balance is reached between MT1-MMP and G6PT expression (i.e., high
MT1-MMP expression, low G6PT expression), cell death signaling is then
activated (3). (B) Our data show that MT1-MMP expression leads to both
proMMP-2 activation (solid line) and to concomitant downregulation of G6PT
expression (dashed line). Conceptually, we suggest that a balance between
the early invasive processes that are initiated by the increased MT1-MMP
expression correlate with proMMP-2 activation to hydrolyze the ECM and
promote cell migration (left, shaded area). Concurrently, G6PT expression
decreases until it reaches a threshold where its inhibitory effect on proMMP-2
activation is released, which then leads to cell death (right area). The inter-
section between the G6PT expression curve and that of the proMMP-2
activation is the bioswitch that reflects the balance between cell invasion and
cell death signaling.
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Interestingly, our data are consistent with some of the
abnormal polymorphonuclear neutrophil phenotypes ob-
served in glycogen storage disease type 1b, a clinical
condition where the G6PT gene and/or protein activity is
defective [52,53]. In fact, it has been hypothesized that G6PT
might function as a G6P receptor/sensor [53] or that it could
favor calcium sequestration in the ER lumen [17]. Finally,
although no effects in response to MT1-MMP or cytoskeleton
disruption were observed on the ER-embedded G6Pase-b,
recent evidence regarding G6Pase-b involvement in cell
survival was demonstrated in neutrophils, as disruption of
the G6Pase-b gene expression also led to cell death, an
event suggestive of a vital interaction between G6PT and
G6Pase-b [54].
In summary, we highlight new functions of MT1-MMP in
cell death signaling that may potentially be linked to those of
the ER-embedded functions of G6PT. In fact, we believe that
this signaling axis may not be exclusive to one cell line, but
rather may regulate cell mobilization processes through
metabolic and/or cell survival control such as similarly dem-
onstrated for bone marrow–derived stromal cells [11]. Our
study further shows a molecular axis linking the invasive
phenotype of brain tumor cells to their potential metabolic
control by G6PT and supports the notion of an MT1-MMP/
G6PT bioswitch (Figure 7B) that could regulate glucose
homeostasis and thus restrain cancer cell proliferation, in-
hibit ECM degradation, or induce cell death. By revealing
tumor-specific metabolic shifts in tumor cells, metabolic
profiling studies will further enable drug developers to identify
the metabolic steps that control cell proliferation, thus aiding
the identification of new anticancer targets and screening of
lead compounds for antiproliferative metabolic effects.
Materials and Methods
Materials
SDS and BSA were purchased from Sigma (Oakville, ON,
Canada). Cell culture medium was obtained from Life Tech-
nologies (Burlington, ON, Canada). Electrophoresis reagents
were purchased from Bio-Rad (Mississauga, ON, Canada).
The enhanced chemiluminescence (ECL) reagents were from
Amersham Pharmacia Biotech (Baie d’Urfe´, QC, Canada).
The polyclonal antibodies against Akt and phospho-Akt were
purchased from Cell Signaling (Danvers, MA). All other
reagents were from Sigma-Aldrich Canada.
Cell Culture and Transfection Method
The U87 glioblastoma cell line was purchased from
American Type Culture Collection (Manassas, VA) and cul-
tured in Eagle’s minimum essential medium (MEM) con-
taining 10% (vol/vol) FBS (HyClone Laboratories, Logan,
UT) and 2 mmol/l glutamine at 37jC under a humidified
atmosphere containing 5% carbon dioxide. U87 glioblastoma
cells were transiently transfected with the cDNA constructs
encoding either the membrane-bound cytoplasmic domain–
truncated MT1-MMP (D-cyto) where the last 20 amino acid
residues were deleted, or the full-length Wt-MT1-MMP fused
to GFP [55], or with 20 nmol/l siRNA (see below) using Lipo-
fectamine 2000 (Invitrogen, Burlington, ON, Canada). The
occurrence of MT1-MMP–specific gene knockdown was
evaluated by semiquantitative RT-PCR and validated by as-
sessing MT1-MMP–mediated proMMP-2 activation. Mock
transfections of U87 cultures with pcDNA (3.1+) or cDNA en-
coding GFP expression vectors alone were used as controls.
RNA Interference
RNA interference experiments were performed using Lipo-
fectamine 2000. An siRNA against MT1-MMP (siMT1-MMP)
and mismatch siRNA were synthesized by EZBiolab Inc.
(Westfield, IN) and annealed to form duplexes. The sequence
of the siMT1-MMP used in this study is as follows: 5V-CCA-
-CCAGAAGCUGAAGGUAGAAdTdT-3V (sense) and 5V-
UUCUACCUUCAGCUUCUGGdTdT-3V (antisense) [24]. The
diminution of MT1-MMP expression, as assessed by RT-
PCR, ranged routinely from 75% to 90% (not shown).
Total RNA Isolation and RT-PCR Analysis
Total RNA was extracted from cultured U87 cells using
TRIzol reagent (Invitrogen). One microgram of total RNA
was used for first-strand cDNA synthesis followed by specific
gene product amplification with the One-Step RT-PCR Kit
(Invitrogen). Primers for G6PT, G6Pase-b, MT1-MMP, and
GAPDH were all derived from human sequences and vali-
dated [13]. PCR conditions were optimized so that the gene
products were examined at the exponential phase of their
amplification and the products were resolved on 1.8% aga-
rose gels containing 1 mg/ml ethidium bromide.
Gelatin Zymography
Gelatin zymography was used to assess the extent
of proMMP-2 activation in conditioned media. Briefly, a
20-ml aliquot of the culture medium was subjected to SDS-
PAGE in a gel containing 0.1 mg/ml gelatin. The gels were
then incubated in 2.5% Triton X-100 and rinsed in nanopure
distilled water. Gels were further incubated at 37jC for
20 hours in 20 mmol/l NaCl, 5 mmol/l CaCl2, 0.02% Brij-35,
50 mmol/l Tris–HCl buffer (pH 7.6), then stained with 0.1%
Coomassie Brilliant Blue R-250 and destained in 10% acetic
acid, 30% methanol in water. Gelatinolytic activity was de-
tected as unstained bands on a blue background.
Immunoblotting Procedures
Proteins from control and treated cells were separated
by SDS-PAGE. After electrophoresis, proteins were electro-
transferred to polyvinylidene difluoride membranes, which
were then blocked for 1 hour at room temperature with 5%
nonfat dry milk in Tris-buffered saline (150 mmol/l NaCl,
20 mmol/l Tris–HCl, pH 7.5) containing 0.3% Tween 20
(TBST). Membranes were further washed in TBST and
incubated with the primary antibodies (1:1000 dilution) in
TBST containing 3% BSA and 0.02% NaN3, followed by a
1-hour incubation with horseradish peroxidase–conjugated
anti– rabbit IgG (1:2500 dilution) in TBST containing 5%
nonfat dry milk. Immunoreactive material was visualized by
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enhanced chemiluminescence (Amersham Biosciences,
Baie d’Urfe´e, QC, Canada).
Analysis of Cell Death by Flow Cytometry
Cell death was assessed by flow cytometry as de-
scribed previously [14]. Adherent and floating cells were
harvested by trypsin digestion and gathered to produce a
single cell suspension. The cells were pelleted by centrifuga-
tion and washed with PBS. Then, 105 cells were pelleted
and suspended in 200 ml of buffer solution and stained with
annexin V–fluorescein isothiocyanate and PI according to the
manufacturer’s protocol (BD Biosciences, Mississauga, ON,
Canada). The cells were diluted by adding 300 ml of buffer
solution and processed for data acquisition and analysis on
a (Becton Dickinson, San Jose, CA) FACS Calibur flow
cytometer using CellQuest Pro software. The x- and y-axes
indicate the fluorescence of annexin V and PI, respectively. It
was possible to detect and quantitatively compare the per-
centages of gated populations in all of the four regions delin-
eated. In the early stages of apoptosis, phosphatidylserine is
well known to translocate to the outer surface of the plasma
membrane, which still remains physically intact. As annexin
V binds to phosphatidylserine but not to PI, and the dye is
incapable of passing the plasma membrane, it is excluded
in early apoptosis (annexin V positive/PI negative). Cells in
late apoptosis are stained with annexin V and PI (annexin V
positive/PI positive). Necrotic cells have lost the integrity of
their plasma membrane and are predominantly stained with
PI (annexin V negative/PI positive).
Statistical Data Analysis
Data are representative of three or more independent
experiments. Statistical significance was assessed by Stu-
dent’s unpaired t test and probability values less than .05
were considered significant; an asterisk (*) identifies such
significance in each figure.
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